Cumberland Pharmaceuticals (NASDAQ:CPIX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a report released on Wednesday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Stock Performance

Shares of CPIX stock opened at $1.61 on Wednesday. The stock has a fifty day moving average price of $1.85 and a 200 day moving average price of $1.88. The stock has a market cap of $22.83 million, a PE ratio of -3.66 and a beta of 0.16. Cumberland Pharmaceuticals has a 1 year low of $1.43 and a 1 year high of $2.36. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.11 and a current ratio of 1.28.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its quarterly earnings data on Tuesday, March 5th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter. The firm had revenue of $9.35 million for the quarter. Cumberland Pharmaceuticals had a positive return on equity of 6.84% and a negative net margin of 15.87%.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

An institutional investor recently bought a new position in Cumberland Pharmaceuticals stock. Bank of New York Mellon Corp purchased a new position in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 75,268 shares of the specialty pharmaceutical company’s stock, valued at approximately $142,000. Bank of New York Mellon Corp owned about 0.52% of Cumberland Pharmaceuticals as of its most recent SEC filing. 15.51% of the stock is currently owned by institutional investors and hedge funds.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.